PHARMACOLOGY AND PHARMACOKINETICS OF CYCLOSPORINE

被引:49
作者
FREEMAN, DJ
机构
[1] Clinical Pharmacology Resource Group, Robarts Research Institute, London, Ont. N6A 5K8
关键词
CYCLOSPORINE; PHARMACOLOGY; PHARMACOKINETICS; METABOLISM; DRUG INTERACTIONS;
D O I
10.1016/0009-9120(91)90084-R
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Cyclosporine (CsA) is a lipophilic, immunosuppressive peptide which selectively inhibits T-lymphocyte activation in response to antigen stimulation. Although it is the drug of choice in organ transplantation, its clinical use is hampered by toxicity and unpredictable pharmacokinetics. CsA absorption from the small intestine is normally incomplete and is further reduced by intestinal dysfunction and low bile flow. That which enters the systemic blood is metabolized almost entirely by the liver and excreted in the bile. Blood CsA levels are altered to a clinically relevant degree by abnormal liver function and by drugs that induce or inhibit hepatic metabolism. Intestinal absorption may also play a role in some drug interactions. The narrow therapeutic range of CsA and the various factors that alter its kinetics underlie the continuing need to monitor this drug in blood.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 64 条
  • [1] VERY HIGH-CONCENTRATION IN INTESTINAL LYMPH AFTER ORAL, BUT NOT AFTER INTRAVENOUS, CYCLOSPORINE IN THE RAT
    ALBRECHTSEN, D
    HELGERUD, P
    RUGSTAD, HE
    DUELAND, S
    [J]. TRANSPLANTATION, 1985, 40 (02) : 220 - 222
  • [2] ATKINSON K, 1983, TRANSPLANT P S1, V15, P230
  • [3] CYCLOSPORINE NEPHROTOXICITY
    BENNETT, WM
    PULLIAM, JP
    [J]. ANNALS OF INTERNAL MEDICINE, 1983, 99 (06) : 851 - 854
  • [4] BENNETT WM, 1988, AM J MED, V49, P584
  • [5] BIOLOGICAL EFFECTS OF CYCLOSPORIN-A - NEW ANTILYMPHOCYTIC AGENT
    BOREL, JF
    FEURER, C
    GUBLER, HU
    STAHELIN, H
    [J]. AGENTS AND ACTIONS, 1976, 6 (04): : 468 - 475
  • [6] BOURBIGOT B, 1986, LANCET, V1, P1447
  • [7] BROWN MR, 1989, ANESTH ANALG, V69, P773
  • [8] BRUNNER LJ, 1988, RES COMMUN CHEM PATH, V59, P339
  • [9] LIPID ABNORMALITIES IN UREMIA, DIALYSIS, AND TRANSPLANTATION
    CHAN, MK
    VARGHESE, Z
    MOORHEAD, JF
    [J]. KIDNEY INTERNATIONAL, 1981, 19 (05) : 625 - 637
  • [10] CHAPPELL LH, 1988, TRANSPLANT P, V20, P291